Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204349 | 1.00 | DPP4 (1.00) | DPP4DPP8CYP3A4 | |
| SCHEMBL27875485 | 1.00 | DPP4 (1.00) | DPP4DPP8CYP3A4 | |
| Cadaverine Tartrate SCHEMBL4215177 | 0.92 | DPP4 (0.85) | DPP4DPP8CYP3A4 | |
| Cadaverine Tartrate SCHEMBL4215175 | 0.92 | DPP4 (0.85) | DPP4DPP8CYP3A4 | |
| SCHEMBL3390924 | 0.90 | DPP4 (1.00) | DPP4DPP8CYP3A4 | |
| SCHEMBL3390926 | 0.90 | DPP4 (1.00) | DPP4DPP8CYP3A4 | |
| SCHEMBL13338124 | 0.90 | DPP4 (0.81) | DPP4DPP8 | |
| SCHEMBL3392459 | 0.89 | DPP4 (1.00) | DPP4DPP8CYP3A4 | |
| SCHEMBL3392462 | 0.89 | DPP4 (1.00) | DPP4DPP8CYP3A4 | |
| SCHEMBL14229884 | 0.89 | DPP4 (0.84) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042863-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | claimed |
| EP-1970063-A1 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-09-17 | — | — | EP | claimed |
| EP-1911754-A1 | Dipeptidyl peptidase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | claimed |
| EP-1506967-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2007-11-21 | — | — | EP | claimed |
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | claimed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | claimed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | claimed |
| US-9427434-B2 | Coated preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-30 | — | — | US | disclosed |
| US-9382188-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| US-9181186-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2172200-B1 | COATED PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2015-09-16 | — | — | EP | disclosed |
| US-20150045378-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| US-8952185-B2 | Production method of optically active dihydrobenzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885CYP3A4 194/4885 |
| US-20150045378-A1 | AROMATIC RING COMPOUND | GPR119, GPR27, GPR4 | DPP4 268/4885DPP8 483/4885CYP3A4 1265/4885 |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885CYP3A4 194/4885 |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885CYP3A4 194/4885 |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885CYP3A4 194/4885 |
| US-20090042863-A1 | Therapeutic Agent for Diabetes | IAPP, GPR119, SLC5A2 | DPP4 12/4885DPP8 40/4885CYP3A4 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.